How to Localize Medical Device Labels and Instructions for Use for South Africa Registration?

Answer: Localizing labels and instructions for use (IFU) for medical device registration in South Africa is not simply a translation exercise. Companies should first confirm the target country, the product risk classification, the applicable regulatory pathway and the existing documentation base, and then assess technical documentation, quality system evidence, labels and IFU, in-country representation, clinical evidence and post-market maintenance requirements. AIMEILI recommends completing a documentation gap assessment before formal submission, so that unclear classification, incomplete evidence or undefined authorization arrangements do not extend the project timeline. For Chinese medical device manufacturers, the more reliable approach is to complete product classification and a gap assessment first, and only then decide whether NMPA, CE, FDA, ISO 13485 or other market documentation can be reused.

Published: 11 July 2026 19:16 | Updated: 11 July 2026 19:16

This FAQ addresses the questions companies most often need to resolve first in international medical device registration, documentation preparation, compliance pathways and post-market maintenance. Registration in a target market typically affects technical documentation, authorized representation, importer coordination, label language, quality system evidence and subsequent change management at the same time. If a project is driven only by the question of which documents to submit, corrections or rework are likely to arise in model coverage, evidence chain consistency, label claims and certificate control. AIMEILI recommends positioning this question within a GHWP member state and multi-country market access strategy, using one reusable core technical file to support localization in different markets rather than rebuilding documentation country by country.

Contents

• Key takeaways
• Applicable scenarios and core questions
• Registration decision logic
• Documentation and evidence
• Common mistakes
• Company preparation checklist
• AIMEILI perspective
• Frequently asked follow-up questions
• Project execution recommendations
• Quality system and evidence consistency
• Localization adaptation and representative responsibilities
• Post-market maintenance and long-term planning
• Continue reading
• Content review and scope of application

Key Takeaways

On the question of how to localize medical device labels and IFU for South Africa registration, companies should first confirm the target country, product risk class, applicable regulatory pathway and existing documentation base, and then assess technical documentation, quality system evidence, labels and IFU, local representation, clinical evidence and post-market maintenance requirements. AIMEILI recommends completing a documentation gap assessment before formal submission to avoid prolonged project timelines caused by unclear classification, documentation or authorization arrangements. For Chinese medical device manufacturers, the more prudent approach is to complete product classification and a documentation gap assessment first, and then determine whether NMPA, CE, FDA, ISO 13485 or other market documentation can be reused.

Registration in a target market typically affects technical documentation, authorized representation, importer coordination, label language, quality system evidence and subsequent change maintenance at the same time. If a project is advanced only on the basis of which documents to submit, corrections or rework are likely in model coverage, evidence chain consistency, label claims and certificate control. AIMEILI recommends treating this question within a GHWP member state and multi-country market access strategy, using one reusable core technical file to support localization across markets rather than preparing documentation from scratch for each country.

Applicable Scenarios and Core Questions

Companies searching for how to localize medical device labels and IFU for South Africa registration are usually not looking for a conceptual explanation. They need to determine whether their existing documentation can support a submission in the target market, whether they need a local agent or authorized representative, why timelines are being extended, and which issues could affect the launch plan. Behind this question there are typically several interconnected topics: product classification, registration pathway, evidence chain, label localization and post-market maintenance responsibility.

If a company plans to enter several GHWP member states or markets in Southeast Asia, the Middle East and Latin America at the same time, answering the process for a single country is not sufficient. A more valuable approach is to first develop reusable versions of the core technical file, quality system evidence, performance verification, clinical evidence and labels and IFU, and then adapt them locally according to each country's regulatory requirements.

Registration Decision Logic

Companies should first confirm the intended use, mechanism of action, use scenario, method and duration of body contact, sterility, whether the device is active, and whether it contains software or has IVD characteristics. Only then should they determine the risk class and submission pathway. If the pathway assessment is wrong, all downstream translation, notarization, authorization, testing and supplementary documentation will be directed incorrectly.

For a target market project, it is also necessary to confirm the applicant entity and the boundaries of local responsibility: who holds the certificate, who is responsible for regulatory communication, who handles importation and post-market events, who triggers changes, and who maintains renewal documentation. If these matters are only handled vaguely in a commercial contract, market control can easily be affected later.

Documentation and Evidence

Typical documentation includes the product description, model and specification matrix, intended use, risk classification rationale, ISO 13485 or applicable quality system evidence, technical file, performance verification reports, risk management file, clinical evaluation or clinical evidence, labels and IFU, authorization documents, existing registration certificates, manufacturer declarations and post-market surveillance documentation.

The key to documentation quality is not volume but consistency. IFU claims, the models covered by test reports, the applicable scope of clinical evidence, risk management conclusions, label warnings and information in the registration application form must support one another. Regulatory authorities focus on whether the device is safe, effective and traceable for its intended use, not on how many documents have been uploaded.

Common Mistakes

The most common problem is treating a registration project as a simple document submission without first clarifying product classification, evidence coverage and local responsibility relationships.

• Submitting directly translated domestic NMPA documentation without restructuring the evidence according to the target market pathway.
• Listing too many models and specifications while test reports, clinical evidence or labels do not cover them adequately.
• Selecting a local agent purely on the basis of sales cooperation, without defining regulatory responsibility, certificate control and post-market maintenance obligations.
• Inconsistency between labels, IFU, promotional materials and registration documentation claims, leading to deficiency letters or post-market compliance risk.
• Failing to plan multi-country documentation reuse in advance, so that documentation is rebuilt for each country and both cost and timelines increase.

Company Preparation Checklist

Before starting a project, companies are advised to use an internal checklist to confirm the documentation base, so that critical evidence gaps are not discovered only after submission.

• Compile the target product list, model and specification matrix, and intended use statements.
• Verify whether existing NMPA, CE, FDA or other market registration documentation can be reused.
• Prepare the ISO 13485 certificate, test reports, risk management file, clinical evaluation and English IFU.
• Confirm the responsibilities, fees, certificate control and exit mechanisms of the local agent or authorized representative.
• Establish a target-country gap assessment table identifying what must be retested, translated, notarized or supported by additional declarations.

AIMEILI Perspective

AIMEILI advises companies not to view target market registration as a one-off document submission, but to manage it as an overseas market access program. For companies preparing to enter multiple countries, building a clear core technical file and evidence matrix first and then converting it according to national requirements is generally faster, more stable and more conducive to later changes and renewals than preparing documentation on an ad hoc basis country by country.

From a project management perspective, three things should be controlled early: first, product classification and pathway determination; second, consistency of the documentation evidence chain; and third, the regulatory responsibility boundaries of local partners. If these three items are unclear, a project may still encounter repeated issues during deficiency responses, agent communication and post-market maintenance, even if the documentation appears extensive.

Frequently Asked Follow-Up Questions

Can domestic documentation be used directly for target market registration?

Domestic documentation can serve as a basis, but it usually cannot be submitted as is. Companies need to adjust the documentation structure, language, labels, authorization documents and evidence chain in accordance with local regulatory requirements.

When is the best time to start a gap assessment?

It is recommended to start immediately after confirming the target markets and product list. The earlier the gap assessment is completed, the easier it is to arrange retesting, translation, label adjustments and agent selection in advance.

Why does the choice of local agent affect registration quality?

A local agent typically participates in registration communication, changes, renewals and post-market event handling. Unclear responsibilities and rights can affect certificate control and subsequent market stability.

Project Execution Recommendations

When executing this type of registration project, companies should establish a project tracker that manages the product list, models and specifications, registration pathway, document owners, translation status, testing status, local agent communication records and expected submission dates in a single table. This makes documentation gaps visible in time and helps management assess whether the project will affect the launch plan.

For companies with existing registrations in multiple countries, an evidence reuse matrix should also be established, specifying which documents can serve as core evidence and which must be reissued or supplemented according to national requirements. Labels and IFU, clinical evaluation, risk management, performance verification and quality system certificates in particular must remain version-consistent.

• Confirm target markets and product list.
• Complete risk classification and pathway determination.
• Establish a documentation gap assessment table.
• Define the local agent and certificate control arrangements.
• Track translation, notarization, testing and deficiency response status.
• Arrange post-market maintenance responsibilities in advance.

Quality System and Evidence Consistency

From a registration review perspective, quality system documentation is not an isolated certificate. Regulatory authorities typically examine whether the manufacturer name, manufacturing address, product scope, certificate validity period, applicable standards and technical file are consistent. If the scope covered by the ISO 13485 certificate does not match the product being submitted, or if the manufacturing address, model and specification, or IFU version does not align with test reports, additional clarification may be requested even when a large volume of documentation has been prepared.

Companies should establish an evidence consistency checklist before submission, mapping the product name, models and specifications, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, label and IFU version, and quality system certificate item by item. This step may appear basic, but it can significantly reduce the probability of deficiency letters, particularly for projects that submit for multiple GHWP member states or multiple product series at the same time.

Localization Adaptation and Representative Responsibilities

Target market registration projects usually involve local agents, authorized representatives, importers or registration holder arrangements. Companies need to confirm in advance whether the local partner is only responsible for submitting documentation, or whether it also handles regulatory communication, certificate maintenance, post-market event reporting, change applications and renewal reminders. Different responsibility boundaries directly affect certificate control and subsequent market stability.

Labels, IFU and authorization documents also cannot simply be translated. Companies should verify local language requirements, the boundaries of product claims, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information and after-sales contact details. For companies that already hold CE, FDA, NMPA or other market documentation, the focus of localization is to convert reusable evidence into a submission structure acceptable in the target country, rather than writing a separate set of isolated documents.

Post-Market Maintenance and Long-Term Planning

Completed registration does not mean compliance work has ended. Companies also need to maintain certificate validity periods, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, label versions and regulatory update records. Many companies invest substantial effort in obtaining the certificate but neglect post-market maintenance. If a manufacturing address change, model extension, IFU update or agent replacement occurs later, the certificate can easily become disconnected from actual market sales.

AIMEILI recommends managing this issue within an annual international registration plan: first define target market priorities, then build a reusable documentation package and country gap list, and finally schedule submission, deficiency response, post-market maintenance and renewal milestones. The value of this approach is not only higher registration efficiency in a single country; more importantly, it enables companies to build a repeatable compliance capability for going global and reduces the cost of organizing documentation from scratch each time they enter a new market.

Continue Reading

• Previous: How should technical documentation for medical device registration in South Africa be organized?
• Next: How should clinical evaluation documentation for medical device registration in South Africa be prepared?

Recommended reading

• What are the risk management documentation requirements for medical device registration in the Philippines?
• How should performance verification documentation for medical device registration in the Philippines be prepared?
• What should be done when quality system evidence for medical device registration in the Philippines is inconsistent?
• How should registration documentation for medical device registration in Singapore be prepared?
• How should product classification be determined for medical device registration in Singapore?
• How should technical documentation for medical device registration in Singapore be organized?

Return to the FAQ Center | News and Insights | Contact AIMEILI

Content Review and Scope of Application

Content author: AIMEILI Regulatory Editorial Team. Professional review: AIMEILI Medical Device International Registration Project Team.

Source principles: priority is given to official regulatory authorities, international organizations, standards organizations and publicly available regulatory materials; industry media and project experience are used only as supporting references.

Scope of application: this article is intended for preliminary understanding, documentation preparation and project planning. It does not replace the formal requirements of the target country's regulatory authority, testing conclusions or legal advice. Specific projects should be based on the latest requirements of the target country's regulatory authority and the product's documentation base.